TransMedics (TMDX) Net Income towards Common Stockholders Growth (1y) (2019 - 2026)
TransMedics (TMDX) Net Income towards Common Stockholders Growth (1y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | -47.84% |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 44.34% |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 18.55% |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | 13.80% |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | -27.18% |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | 38.54% |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 14.80% |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | 73.85% |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | 12.92% |
| 10 | TransMedics | 3.15 Bn | 2.67 Bn | 113.20 Mn | -57.91% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -57.91% |
| Mar 31, 2026 | -71.51% |
| Dec 31, 2025 | 539.21% |
| Sep 30, 2025 | 476.83% |
| Jun 30, 2025 | 186.06% |
| Mar 31, 2025 | 110.51% |
| Dec 31, 2024 | -1,525.10% |
| Sep 30, 2024 | 116.58% |
| Jun 30, 2024 | 1,318.18% |
| Mar 31, 2024 | 562.71% |
| Dec 31, 2023 | 129.70% |
| Sep 30, 2023 | -242.34% |
| Jun 30, 2023 | 91.31% |
| Mar 31, 2023 | 75.04% |
| Dec 31, 2022 | 47.54% |
| Sep 30, 2022 | 42.71% |
| Jun 30, 2022 | -8.01% |
| Mar 31, 2022 | -33.41% |
| Dec 31, 2021 | -100.22% |
| Sep 30, 2021 | -154.76% |